Akarna Therapeutics Secures $15,000,000 Series B Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=2c23beed-fc6a-4737-be25-32c4af28f6f6 - Date
2/17/2016 - Company Name
Akarna Therapeutics - Mailing Address
1012 Second Street Encinitas, CA 92007 USA - Company Description
Akarna Therapeutics is a biopharmaceutical company developing novel small molecule therapeutics that target inflammatory and fibrotic diseases for which there is no approved treatment. - Website
http://www.akarna.com - Transaction Type
Venture Equity - Transaction Amount
$15,000,000 - Transaction Round
Series B - Proceeds Purposes
Akarna will use the funds to accelerate the development of its lead FXR agonist drug candidate through human proof-of-concept studies in patients with non-alcoholic steatohepatitis (NASH), a progressive form of fatty-liver disease for which there are no approved therapies. - M&A Terms
- Venture Investor
Forbion Capital Partners - Venture Investor
New Science Ventures - Venture Investor
Third Point
